New report sets out six case studies of drug makers that are increasing local access to antibiotics and antifungals, including through technology transfers and partnerships. People in low- and middle-income countries cannot get the antibiotics and antifungal medicines they need. This is fuelling the spread of drug resistance.

A series of articles from the Access to Medicine Foundation stress the urgent need for new “child-friendly” treatments for HIV, malaria and TB to end the burden these diseases have on children, especially with the looming impact of COVID-19 and emerging drug resistance.

In a new report the Access to Medicine Foundation shows where pharmaceutical companies have made progress in the past ten years when it comes to access to medicine. It analyses companies’ performances in 106 low- and middle-income countries – home to 83% of all people alive today.

The 2018 Access to Medicine Index finds that a handful of pharmaceutical companies are developing the bulk of urgently needed new medicines for the poor.

The Benchmark compares how a cross-section of the pharmaceutical industry is responding to the threat from drug-resistant infections. It measures the 30 most active players in antimicrobial development and production and includes multinational pharmaceutical companies, biotechnology firms and manufacturers of generic medicines.